摘要
目的:单纯疱疹病毒Ⅰ型胸苷激酶(HSV-tk)基因治疗恶性胶质瘤体内外试验。方法:分子克隆及真核细胞基因转染技术构建逆转录病毒(RV)载体pMV7(tk)及PA317tk包装细胞系;体外不同比例混合鼠C6胶质瘤细胞与PA317tk细胞,在GCV(Ganciclovir)作用下观察细胞存活率;建立SD大鼠颅内C6胶质瘤模型(种植5×105C6细胞),治疗组第3天原位注射5×106PA317tk细胞,5天后腹腔给予GCV(30mg/kg.d),MRI全程监测肿瘤消长,观察病症及存活期,并行病理检查。结果:在GCV0.1~101μg/ml浓度范围内,C6细胞存活率随PA317tk细胞混入比例增加而逐渐减低(P<0.001),并具有GCV剂量依赖性(P<0.01);体内试验治疗组病症轻,生存期延长,MRI表明治疗组肿瘤体积较对照组明显减小(P<0.01),1个月时病理检查见肿瘤细胞消失,代之以小胶质细胞增生并形成坏死囊。结论:应用本实验室构建的RV载体pMV7(tk)及其PA317tk包装细胞系治疗恶性胶质瘤是一种有效及具有前途的治疗方法。
Objective: To study the effects of Herpes Simplex virus type 1 thymidine kinase (HSV-tk) gene and Ganciclovir (GCV)therapeutic system for malignant glioma in vitro and in vivo Methods: We constructed retrovirus (RV) vector bearing HSV-tk gene and established its packaging cell line PA317tk using the technique of molecular cloning and gene transfection for eukaryotic cells respectively; C6 glioma cells were mixed with PA317tk cells in various percentages and exposed to GCV in vitro, cell survival rate was determined with MTT method; C6 glioma model in vivo was established in SD rat (5105 C6 cells xenograft);5106 PA317tk cells were injected in situ on the third day after tumor cells xenograft GCV was administrated ip at the dose of 30mg/kg/day 5 days later Tumor growth or regression was monitored with MRI General manifestation after implantation with C6 glioma cells, survival time and pathological examination were also observed Results: Survival rate of C6 cells was negatively correlated with the percentage of PA317tk cells added (P< 0001), and its reduction was GCV dose dependent (P< 001) Milder symptomatic manifestation, longer survival and smaller tumor volume were obvious in the treatment group as compared to the control group Tumor cells almost disappeared and were replaced with the proliferation of glial cells and the formation of necrotic cyst Conclusion: The treatment of glioma using RV vector pMV7 (tk) and its packaging cell line PA317tk constructed and established in our laboratory is an effective and prospective modality of treatment
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1999年第6期405-408,共4页
Chinese Journal of Clinical Oncology